Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.

Callie Berkowitz Samuel Wilson Nigel S Key Patrick Ellsworth

J Thromb Haemost

Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Carolina Blood Research Center, Chapel Hill, North Carolina, USA. Electronic address:

Published: September 2024

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jtha.2024.04.027	DOI Listing

Publication Analysis

Top Keywords

comparison thrombotic

thrombotic adverse

adverse events

events patients

patients treated

treated factor

factor viii

viii products

products emicizumab

emicizumab 2018-2022

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!